Idarubicine Accord (Idarubicin Hydrochloride)

Idarubicin is an anthracycline antineoplastic agent used in the treatment of hematologic malignancies.

• Acute myeloid leukemia (AML): induces remission by targeting rapidly dividing leukemic blasts.
• Relapsed or refractory AML: provides an alternative therapeutic option when standard regimens fail.
• Acute lymphoblastic leukemia (ALL): contributes to disease control through DNA damage in lymphoid blasts.

• Idarubicin intercalates between DNA base pairs and inhibits topoisomerase II, preventing the resealing of DNA strands during replication. This results in double‑strand breaks, generation of free radicals, and ultimately cytotoxic death of rapidly proliferating malignant cells.

Idarubicine Accord may cause a range of adverse reactions.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset common during infusion.
• Myelosuppression: reduced white blood cells, platelets, and red cells.
• Alopecia: hair loss that may be temporary.
• Fatigue: generalized tiredness during treatment.
• Mucositis: inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects

• Cardiotoxicity: irreversible heart damage, especially at high cumulative doses.
• Severe neutropenia or febrile neutropenia: increased infection risk.
• Secondary malignancies: rare development of new cancers.
• Hepatic toxicity: elevated liver enzymes or liver dysfunction.
• Severe infusion reactions: hypotension, dyspnea, or anaphylaxis.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor organ function.

• Cardiac monitoring: baseline and periodic ejection fraction assessment due to risk of cardiotoxicity.
• Hematologic monitoring: regular complete blood counts to detect myelosuppression.
• Renal and hepatic function: evaluate and adjust therapy in patients with impairment.
• Concomitant cardiotoxic agents: avoid or use with caution to limit additive heart damage.
• Pregnancy and lactation: use only if potential benefits justify potential risks; data are limited.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Idarubicine Accord can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Other anthracyclines: additive cardiotoxicity.
• Live vaccines: heightened infection risk due to immunosuppression.
• Strong CYP3A4 inhibitors: may increase idarubicin exposure.
• Chest radiation therapy: synergistic cardiac toxicity.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may alter metabolism.
• Cyclophosphamide: overlapping myelosuppressive effects.
• Granulocyte‑colony stimulating factors: may affect blood count recovery.